Sucampo to Host 2017 R&D Day on November 16 in New York
November 09, 2017 17:48 ET | Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its 2017 R&D Day...
Sucampo Reports Third Quarter 2017 Financial Results
November 01, 2017 06:30 ET | Sucampo Pharmaceuticals Inc
Company Increases 2017 Financial Guidance Based on Strong Performance Year to Date Study Results for VTS-270 for Niemann-Pick Disease Type C1 Published in The Lancet CPP-1X/sulindac Granted...
Sucampo Reports Second Quarter 2017 Financial Results
August 02, 2017 06:30 ET | Sucampo Pharmaceuticals Inc
Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse...
Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
June 13, 2017 16:30 ET | Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., June 13, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the U.S. Patent and Trademark Office...
Sucampo Reports First Quarter 2017 Financial Results
May 03, 2017 06:30 ET | Sucampo Pharmaceuticals Inc
Continued Revenue Growth Recent Vtesse Acquisition Bolsters Pipeline Company Reiterates 2017 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT ROCKVILLE, Md., May 03, 2017 (GLOBE...